CY2019 Home Health Prospective Payment System Proposed Rule: HFMA Executive Summary
This document summarizes the proposed rule updating payment rates under the home health PPS for CY2019, published by CMS.
Azar Promises Drugmaker Penalty Rule Coming
July 9—A five-times-delayed rule that would stiffen drugmaker penalties—among other provisions—will be implemented, the Trump administration’s healthcare policy leader told providers on Monday.
Transparency, Interoperability, DSH Changes Lead Hospital IPPS Concerns
July 6—Hospital advocates recently raised a range of concerns about proposed Medicare payment policy changes, including transparency and interoperability requirements and a new way to calculate uncompensated care payments.
HFMA Comments on FY2019 IPPS Proposed Rule
HFMA submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the FY2019 IPPS proposed rule published in the May 7, 2018, Federal Register.
Will CPC Model’s Failings Follow into CPC+?
June 1—Improving the practice of medicine at the primary care level by deploying massive, publicly-funded incentives is complicated, but doable on the margins.
FY2019 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Requirements
This document summarizes the FY2019 proposed rule updating the hospice wage index and payment rates.
Bundled Payments for Care Improvement Advanced: 5 Critical Issues
When considering whether to participate in the Bundled Payments for Care Improvement Advanced program, hospitals and health systems should examine five key areas that could affect their performance under the program.
Areas of Healthcare Policy Agreement Would Target Hospitals
May 25—Emerging areas of bipartisan health policy agreement include hospital-targeted policies, according to policy experts.
Decoding MSPB: Trending Better Faster
Dale Schumacher and Fern Nerhood describe how trends in Medicare spending per beneficiary can affect hospital finances.
340B Targeted in Trump Administration Drug Push
May 15—Hospital advocates and others raised concerns about impacts of the Trump administration’s recently announced initiative to address rapidly rising drug prices in part through policy changes to an existing drug discount program.